MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totaling 956,179 shares, an increase of 2,794.0% from the June 30th total of 33,040 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average daily volume of 662,840 shares, the days-to-cover ratio is currently 1.4 days.

Institutional Trading of MDxHealth

A number of institutional investors and hedge funds have recently modified their holdings of MDXH. Intesa Sanpaolo Wealth Management purchased a new position in MDxHealth in the 4th quarter valued at about $36,000. Lido Advisors LLC purchased a new stake in MDxHealth during the 3rd quarter worth approximately $48,000. Squarepoint Ops LLC acquired a new position in shares of MDxHealth during the fourth quarter valued at approximately $51,000. Jefferies Financial Group Inc. acquired a new position in shares of MDxHealth during the third quarter valued at approximately $53,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of MDxHealth during the fourth quarter valued at approximately $68,000.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MDXH. TD Cowen reissued a “buy” rating and set a $1.50 price target (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. BTIG Research cut their price objective on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Lake Street Capital decreased their price objective on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Wall Street Zen lowered shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, William Blair cut MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $3.50.

MDxHealth Price Performance

Shares of MDXH stock opened at $0.41 on Friday. The company has a market cap of $20.30 million, a price-to-earnings ratio of -0.63 and a beta of 1.43. The stock has a 50 day simple moving average of $0.56 and a 200-day simple moving average of $2.11. MDxHealth has a 1-year low of $0.40 and a 1-year high of $5.33.

MDxHealth (NASDAQ:MDXH) last announced its earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $30.89 million. Analysts anticipate that MDxHealth will post -0.6 earnings per share for the current fiscal year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.